Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

PCSK9 inhibitors are another medication. “PCSK9 inhibitors are drugs that block the PCSK9 protein, which reduces LDL receptor ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...

While the efficiency of PCSK9 mAbs, mipomersen and lomitapide has been demonstrated in FH patients, there has been no completed trial with new CETP inhibitors in FH, but one trial is underway ...

In June, AstraZeneca announced the interim results of its phase 1 trial of AZD0780, an oral small molecule PCSK9 inhibitor, which evaluated the safety and tolerability of the drug in healthy adults.